GARDP together with DNDi published a policy briefing statement at the 74th World Health Assembly. According to the statement, the lessons from the COVID-19…
CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class of antibiotics to treat Gram-negative bacterial infections. The…
Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics manufacturing network by further expanding production capabilities in…
Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital is provided for the development of first-in-class antibiotics against…
BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten years. It will set upon the results delivered…